Celexa/Lexapro MDL winds up
Celexa/Lexapro MDL winds up
Introduction
The U.S. District Judge Nathaniel M. Gorton granted Forest Laboratories’ motion for summary judgment on all claims made by the plaintiffs who alleged that the company fraudulently promoted Celexa and Lexapro for pediatric depression. This ruling brings an end to the long-running Massachusetts MDL 2067: In Re: Celexa and Lexapro Marketing and Sales Practices Litigation.
Comments
Latest News
Court Approves $700M Opioid Settlement for Acute Hospitals
Categories: Opioids
A federal court has approved a $700 million class-action settlement that will compensate over 1,000 acute care hospitals for costs related to the opioid crisis.
The settlement consolidates four separate agreements involving major drug…
Philips Settles CPAP Lawsuits Over Toxic Foam for $1.1B
Categories: Philips CPAP/BiPAP/ASV Sleep Apnea Machines
Philips has been embroiled in legal battles following the recall of millions of CPAP, BiPAP, and ventilator devices due to toxic foam degradation.
The breakdown of the foam in these machines may release harmful chemicals, raising serious…
Texas Trial to Decide J&J’s $10B Talcum Powder Settlement
Categories: Talcum
A high-stakes trial in Texas will determine whether Johnson & Johnson (J&J) can resolve tens of thousands of talcum powder cancer lawsuits through a…